Todd Horich, Ph.D., MBA
Esta página aún no está disponible en tu idioma.
Todd Horich, Ph.D., MBA, is Senior Vice President and Chief Commercial Officer at Supernus Pharmaceuticals. His relevance to the botulinum toxin industry comes from Supernus commercial leadership for CNS portfolio products, including Myobloc / Neurobloc.
Horich’s role helps separate commercial organization from product origin. Myobloc entered Supernus through the US WorldMeds CNS portfolio transaction, while Horich explains the commercial infrastructure around Supernus’s current portfolio.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Supernus Pharmaceuticals |
| Current role | Senior Vice President and Chief Commercial Officer |
| Industry relevance | Supernus commercial leadership for Myobloc and CNS portfolio context |
| Relevant company | Supernus Pharmaceuticals |
| Relevant brand | Myobloc / Neurobloc |
| Market context | Commercial organization, acquisition integration, and neurology-product launches |
Career Notes
Section titled “Career Notes”- Supernus states that Horich was appointed Senior Vice President and Chief Commercial Officer in March 2026.
- Supernus describes his role in building the company’s marketing, market access, commercial operations, and commercial-development functions.
- Supernus lists Myobloc among its commercial products.
- Supernus’s product list frames Myobloc inside a therapeutic CNS portfolio rather than an aesthetic type A neuromodulator portfolio.
Commercialization Context
Section titled “Commercialization Context”Horich matters because a reader asking who is behind Myobloc may need both the company answer and the commercial-organization answer. Supernus is the current U.S. company context; Myobloc itself remains rimabotulinumtoxinB and should be interpreted through its label.
That commercial role does not make Myobloc directly comparable with type A products by unit count, duration, approved use, or patient population.
Activity and Public Context
Section titled “Activity and Public Context”Horich’s Supernus and Myobloc relevance is current commercial leadership. Jonathan Rubin, MD, MBA anchors medical and R&D leadership, while Jack A. Khattar anchors company leadership.